Bleeding News and Research

RSS

FDA warns about 'liberation therapy' for multiple sclerosis

The U.S. Food and Drug Administration is alerting health care professionals and patients about injuries and death associated with the use of an experimental procedure sometimes called "liberation therapy" or the "liberation procedure" to treat chronic cerebrospinal venous insufficiency (CCSVI).

11 May 2012

Research roundup: Health providers' growing clout; The surprising bargain in Part D costs

The Growing Power Of Some Providers To Win Steep Payment Increases From Insurers Suggests Policy Remedies May Be Needed -- Concerns have grown that the consolidation of hospitals and physician groups has increased their ability to raise prices, which increases costs for insurers and patients.

11 May 2012

Janssen submits XARELTO sNDA with FDA to reduce risk of stent thrombosis in ACS patients

Janssen Research & Development, LLC announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of XARELTO, an oral anticoagulant, to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome.

10 May 2012

Viewpoints: Taking aim at 'superbugs'; Friending organ donations; Ariz. and Kansas abortion efforts hurt women

In the battle between humans and infectious bacteria, humans have had the advantage, at least since antibiotics were introduced into our arsenal 70 or so years ago. Now, however, our weapons appear to be turning against us as germs have found ways to outfox antibiotics…. A second challenge is to keep a steady stream of new antibiotics in the pipeline, and this is where the big pharmaceutical companies based in Europe and the U.S. come in….

9 May 2012

Medtronic’s Valiant Captivia Stent Graft now available in seven countries

Increasing patient access to endovascular repair of aortic aneurysms worldwide, Medtronic, Inc. is expanding availability of the Valiant Captivia Thoracic Stent Graft System in several countries, including China, Japan and the United States.

From Medtronic 9 May 2012

Survey: Many people do not know how to spot skin cancer

Doing a little detective work can go a long way in finding skin cancer, the most common form of cancer diagnosed in the United States, at its earliest, most treatable stage. However, a new survey found that many people do not know how to spot skin cancer and are unaware of their risk of developing the disease.

8 May 2012

Many unaware that persistent cough could be a warning for lung cancer

Most people are aware that that a lump in the breast is a warning sign of breast cancer and bleeding could indicate bowel, kidney or bladder cancer. However, only one in ten people knows that a persistent cough could point to lung cancer.

8 May 2012

Positive long-term outcome data for chronic ITP patients treated with rituxamab

A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).

7 May 2012

Research identifies molecular trigger of fibroid uterine tumors

Fibroid uterine tumors affect an estimated 15 million women in the United States, causing irregular bleeding, anemia, pain and infertility. Despite the high prevalence of the tumors, which occur in 60 percent of women by age 45, the molecular cause has been unknown.

5 May 2012

Aspirin versus warfarin for heart failure patients

In a new study on more than 2,000 patients, published in the New England Journal of Medicine, researchers found that aspirin was as effective as the commonly prescribed drug warfarin. It said each drug had risks, but they had similar benefits overall.

4 May 2012

Alnylam first quarter revenues decrease to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2012, and company highlights.

4 May 2012

One in six prescriptions may carry a medication error: GMC survey finds

A new study has found that more than one in six patients who are put on medication after seeing their GP are given a prescription containing an error. The study comes from the General Medical Council.

3 May 2012

Large-scale, patient-specific simulations of blood function

Having a virtual copy of a patient's blood in a computer would be a boon to researchers and doctors. They could examine a simulated heart attack caused by blood clotting in a diseased coronary artery and see if a drug like aspirin would be effective in reducing the size of such a clot.

3 May 2012

Johnson & Johnson announces acquisition of Bioseal

Johnson & Johnson (China) Investment Ltd. today announced it has acquired Guangzhou Bioseal Biotechnology Co., Ltd. (Bioseal) a privately held biopharmaceutical company specializing in the design, development and commercialization of a porcine plasma-derived biologic product for controlling bleeding during surgery.

3 May 2012

Study confirms that COX-2 inhibitors predispose people to cardiovascular disease

After nearly 13 years of study and intense debate, a pair of new papers from the Perelman School of Medicine, at the University of Pennsylvania have confirmed exactly how a once-popular class of anti-inflammatory drugs leads to cardiovascular risk for people taking it.

3 May 2012

Thoratec first quarter revenues increase 27% to $126.8M

Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that revenues for the first quarter of 2012 were $126.8 million, an increase of 27% versus revenues of $99.5 million in the same period a year ago.

2 May 2012

Aspirin can reduce chance of dying from bowel cancer by 30%

Taking aspirin after being diagnosed with bowel cancer can reduce the chance of dying from the disease by 30 per cent, new research shows today.

27 Apr 2012

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with kidney tumors known as renal angiomyolipomas and tuberous sclerosis complex (TSC), who do not require immediate surgery.

27 Apr 2012

Novartis receives FDA approval for Afinitor to treat renal angiomyolipomas caused by TSC

The U.S. Food and Drug Administration approved Afinitor (everolimus), the first drug approved specifically to treat non-cancerous kidney tumors (renal angiomyolipomas) not requiring immediate surgery in patients with tuberous sclerosis complex.

27 Apr 2012

Aspirin reduces bowel cancer death and lung cancer incidence: Research suggests

There is previous evidence suggesting aspirin might prevent certain cancers from developing in the first place. And more recent work suggests it might also work as a cancer therapy - slowing down or preventing a cancer's spread. But the drug can also have unpleasant and dangerous side effects, causing irritation of the stomach lining and internal bleeds in a very small minority of patients.

26 Apr 2012